Abstract
Purpose Sleep aids derived from traditional plant medicines are strong candidates for safely improving insomnia but require wider validation in patient populations.
Methods We conducted an open label trial of the impact of a compound, Sip2Sleep®, containing Montmorency tart cherry (prunus cerasus) extract and Venetron® (apocynum venetum) on subjective sleep quality, subjective daytime alertness, sleep duration, sleep latency, anxiety, and insomnia in 43 adults with moderate to severe insomnia. Participants collected data over four weeks, with the sleep aid consumed prior to bed during weeks two and four.
Results The Montmorency tart cherry and Venetron® mixture statistically improved subjective sleep quality, daytime alertness, insomnia symptoms, and anxiety without impacting sleep duration and latency. Subjective improvements in sleep quality exhibited a statistical upward trend across the entire study window, suggesting potential persistence of the compounds days after consumption and greater improvement with longer-term consumption.
Conclusions The combination of Montmorency tart cherry and Venetron® in this commercially available tincture is a promising sleep aid warranting further investigation in larger trials.
Competing Interest Statement
RPP is the founder/CEO of (Lakshmi Nutraceuticals LLC), the maker of Sip2Sleep and an expert sleep physician. He contributed to study design and manuscript review and was not involved in the preparation of results. All other authors are employed by People Science Inc., a contract research & participatory research organization that conducts trials of alternative and adjunctive therapies.
Clinical Trial
NCT06299488
Clinical Protocols
https://clinicaltrials.gov/study/NCT06299488
Funding Statement
This study was funded by Lakshmi Nutraceuticals.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study and all procedures were approved by the Advarra Institutional Review Board (IRB) under Pro00068483. All participants gave informed consent. All research was performed in accordance with relevant guidelines and regulations. This protocol was registered at clinicaltrials.gov under NCT06299488, 07/03/2024.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data and Code Availability: Data and code needed to create the figures in this manuscript are available at Open Science Framework: DOI 10.17605/OSF.IO/F8YV9
Data Availability
All data produced in the present study are available upon reasonable request to the authors
